Lifestyle, Exercise and Diet: The LEAD Study

Age-Related Cognitive Decline Clinical Trial

— LEAD  

Official title:

Nutrition, Exercise and Lifestyle: Team 6 of the Canadian Consortium on Neurodegeneration in Aging (CCNA)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03056508
• Other study ID #: CCNA-NELT
• Status: Terminated
• Phase: N/A
• Start date: July 1, 2018
• Est. completion date: October 8, 2020

Study information

• Verified date: October 2020
• Source: Rotman Research Institute at Baycrest
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will explore the impact of an exercise and nutrition (EX+NUTR) , relative to exercise alone (EX) intervention, on brain structure and function as well as blood biomarkers in older adults with subjective cognitive decline (SCD) and vascular risk factors. The overall hypotheses are that a combined EX+NUTR, relative to EX, intervention will evoke more positive changes in brain structure (e.g. hippocampal volume), neural activity (e.g. task associated functional activations monitored through fMRI), and cognitive performance. These changes will be associated with an improved metabolic profile, reductions in inflammatory cytokines and oxidative burden, and greater intervention compliance.

Description:

All participants will engage in group supervised exercise sessions once per week as well as engage in additional exercise sessions at home 4 days/week. The exercise program will be run out of two sites (Toronto Rehabilitation Institute (TRI) - Rumsey Centre in Toronto, and the Centre for Community, Clinical Applied Research Excellence (CCCARE) at the University of Waterloo). The supervised exercise sessions modeled after the standard TRI Cardiovascular Prevention and Rehabilitation program, including aerobic training, resistance training and education/counseling. The active group will receive strategy training to simultaneously improve their diet in conjunction with our newly developed Brain Health Food Guide (EX+BHFG); the placebo control group (EX+BHEd) will receive brain health education to control for time and social participation. [NOTE All participants must also be enrolled in the SCD cohort of the CCNA and undergo the CCNA's COMPASS-ND assessment at the beginning of the trial.] The study is 6 months in duration and requires participants to attend 2.5 hr weekly sessions (1 hr supervised exercise, 0.5 hr exercise/stress education and 1 hr nutrition or brain health education) and to exercise on their own an additional 3-4 times per week. Participants are assessed on measures of cognition, brain health (MRI), functional status at baseline, post intervention and 6 month follow-up.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 14
• Est. completion date: October 8, 2020
• Est. primary completion date: October 8, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years to 85 Years

Eligibility

Inclusion Criteria:

• meeting criteria for subjective cognitive impairment (1 through 5 below)

1. Answer Yes to both following questions:

1. Do you feel like your memory or thinking is becoming worse?

2. Does this concern you?

2. Have a delayed recall score on 1 paragraph of the Logical Memory test (Wechsler Memory Scale, maximum score 25) above the education-adjusted cut-offs:

• =9 for 16+ years of education;

• =5 for 8-15 years of education;

• =3 for 0-7 years of education.

3. Have a Montreal Cognitive Assessment (MoCA) total score of 20 and over (=20/30).

4. Have a delayed recall score on the CERAD word list of 5 and over (=5).

5. Have a global Clinical Dementia Rating score (CDR) equal to 0.5 or less (=0.5).

• =2 vascular risk factors (overweight (BMI>25), T2DM, hypercholesterolemia or hypertension),

• Consuming a poor quality diet (at least median or below on number of servings of vegetable, fruit, fish and nuts based on Canadian consumption patterns in older adults)

• Reasonably sedentary (less than 75min per week of moderate - vigorous intensity physical activity)

• Be available for the whole intervention (6 months) and a 12- month follow-up visit

• English speaking

Exclusion Criteria:

• The presence of significant known chronic brain disease such as: moderate to severe chronic static leukoencephalopathy (including previous traumatic injury), multiple sclerosis, a serious developmental handicap, malignant tumors, Parkinson's disease, and other rarer brain illnesses.

• Ongoing alcohol or drug abuse that in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures.

• Subject does not have a study partner who can provide corroborative information.

• Symptomatic stroke within the previous year.

• Unable to undergo MRI scan due to medical contraindications or inability to tolerate the procedure.

• Major surgery within last 2 months.

• History of intracranial surgery

• Serious comorbid condition that, in the opinion of the study investigator, is likely to result in death within a year.

• High performance athletes

Related Conditions & MeSH terms

• Age-Related Cognitive Decline
• Cognitive Dysfunction
• Subjective Cognitive Decline

Intervention

Behavioral:
• Exercise plus nutrition
On the same day as the exercise class, participants will also receive nutrition support. Participants will alter their overall diet to be consistent with recommendations outlined in our brain health food guide (BHFG) and receive diet counseling and strategy training to promote retention and enable this dietary change. For the first two months, diet group sessions will be held on a weekly basis. For the remaining four months, sessions will be divided between group sessions and individual meetings with study dietitians, on a predefined schedule. Participants will submit weekly logs outlining diet goals, plans, successes and obstacles to help direct identification of sequential goals.
• Exercise
Supervised group exercise will be performed once per week (60 minutes) and self-directed exercise (4 additional aerobic and 2-3 resistance training sessions per week) will be monitored by an exercise diary. The initial walking prescription will be set at ~1.6 km and an intensity equivalent to the anaerobic threshold and/or 60% VO2-peak. Progressions will be made every 2 weeks, increasing distance to a maximum of 6.4 km and then increasing to a max intensity of 80% of VO2-peak and/or max duration of 60 minutes. Heart rate and perceived exertion will be monitored. The program will last 6 months.

Locations

Country	Name	City	State
Canada	Rotman Research Institute	Toronto	Ontario
Canada	Sunnybrook Health Sciences Centre	Toronto	Ontario
Canada	Toronto Rehabilitation Institute Rumsey Centre	Toronto	Ontario
Canada	Centre for Community, Clinical Applied Research Excellence (CCCARE) at the University of Waterloo	Waterloo	Ontario

Sponsors (5)

Lead Sponsor	Collaborator
Rotman Research Institute at Baycrest	Sunnybrook Health Sciences Centre, The Centre for Memory and Aging, Toronto Rehabilitation Institute, University of Waterloo

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes from baseline brain structure at 6 months and 12 months.	Cortical and subcortical grey matter density using MRI three-dimensional T1 weighted structural scan (MPRAGE)	6 months plus 6 month follow-up
Secondary	Changes from baseline cerebral blood flow at 6 months and 12 months.	Pseudo-continuous arterial spin labeling MRI (pcASL) to quantify cerebral blood flow	6 months plus 6 month follow-up
Secondary	Changes from baseline cognition at 6 months and 12 months	pen and paper and computerized tasks, monitoring memory, executive function, and speed of processing. The results will be presented as a composite score of total neuro-psychological performance aggregating scores from the above cognitive domains.	6 months plus 6 month follow-up
Secondary	Changes from baseline brain activity related to attention at 6 months and 12 months	BOLD functional MRI while participants performing an attention task	6 months plus 6 month follow-up
Secondary	Changes from baseline resting state connectivity at 6 months and 12 months	BOLD functional MRI while participants at rest	6 months plus 6 month follow-up
Secondary	Changes from baseline diet quality at 6 months and 12 months	Principle component analyses based on Canadian Diet History Questionnaire II (C-DHQII)	6 months plus 6 month follow-up
Secondary	Changes from baseline adherence to diet recommendations at 6 months and 12 months	Principle component analyses based on the Eating Pattern Self-Assessment	6 months plus 6 month follow-up
Secondary	Changes from baseline grip strength at 6 months and 12 months	Grip strength using a hand held dynamometer	6 months plus 6 month follow-up
Secondary	Changes from baseline gait performance at 6 months and 12 months	Gait velocity, stride length/width, and associated variability assessed using a GAITRite pressure sensor mat.	6 months plus 6 month follow-up
Secondary	Changes from baseline balance performance at 6 months and 12 months	Posturography assessment on balance platform	6 months plus 6 month follow-up
Secondary	Changes from baseline maximal oxygen uptake at 6 months and 12 months	VO2max determined during cardiopulmonary assessment	6 months plus 6 month follow-up
Secondary	Changes from baseline blood moderators at 6 months and 12 months	e.g. BDNF, pro-BDNF, ApoE,	6 months plus 6 month follow-up
Secondary	Changes from baseline HbA1C at 6 months and 12 months	HbA1C	6 months plus 6 month follow-up
Secondary	Changes from baseline fasting glucose at 6 months and 12 months	fasting glucose	6 months plus 6 month follow-up
Secondary	Changes from baseline insulin levels at 6 months and 12 months	insulin	6 months plus 6 month follow-up
Secondary	Changes from baseline lipid levels at 6 months and 12 months	lipid profile	6 months plus 6 month follow-up
Secondary	Changes from baseline homocysteine levels at 6 months and 12 months	homocysteine	6 months plus 6 month follow-up
Secondary	Changes from baseline C reactive protein levels at 6 months and 12 months	CRP	6 months plus 6 month follow-up
Secondary	Changes from baseline TNF-alpha levels at 6 months and 12 months	TNF-alpha	6 months plus 6 month follow-up
Secondary	Changes from baseline IL6 levels at 6 months and 12 months	IL6	6 months plus 6 month follow-up
Secondary	Changes from baseline vitamin K levels at 6 months and 12 months	Vitamin K	6 months plus 6 month follow-up